Enterprise Value

141.8M

Cash

421.2M

Avg Qtr Burn

-52.63M

Short % of Float

5.39%

Insider Ownership

5.70%

Institutional Own.

80.45%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KSI-301 (GLOW) Details
Non-proliferative diabetic retinopathy

Big Mover™

Susp. Mover™

Phase 3

Data readout

KSI-301 (anti-VEGF) Details
Diabetic macular edema

Big Mover™

Susp. Mover™

Phase 3

Data readout

KSI-301 (BEACON) Details
Retinal vein occlusion

Phase 3

Update

KSI-301 (DAZZLE) Details
Wet age-related macular degeneration

Big Mover™

Susp. Mover™

Phase 2/3

Data readout

KSI-501 (anti-VEGF) Details
Diabetic macular edema, Eye disease

Phase 1

Data readout